Welcome to the new online home of the pharma industry

20/05/2013

Paul Tunnah

You might have noticed that things have changed on pharmaphorum recently, with the launch of our new website, so Paul Tunnah muses this month on some of the key changes...

Finding the right way to listen to patients

20/05/2013

Carly Brown

As our market access month continues and pharma seeks closer patient engagement to better understand real-world outcomes, Carly Brown outlines a number of ways to conduct patient research and weighs...

The reimbursement environment in Europe

17/05/2013

Sophia Tickell

In our market access themed month, Sophia Tickell comments on the reimbursement landscape in healthcare across Europe. For decades, Europe's labs and R&D centres produced world-beating innovation. A different innovation of...

The enemy within

17/05/2013

Sam Olsen

Sam Olsen warns that the greatest threat to Pharmaceutical and Biotech corporate Intellectual Property (IP) security comes from within. He says that that companies should not just consider if their...

Actavis to acquire Warner Chilcott for $8.5bn

20/05/2013

Hannah Blake

Generic drugmaker Actavis has entered into a definitive agreement to acquire the international pharma company Warner Chilcott plc for US $8.5 billion. If successfully completed, this transaction will create the third-largest...

India’s new drug pricing policy comes into effect

20/05/2013

Hannah Blake

The Government of India's Department of Pharmaceuticals announced last week that the Drug Price Control Order 2013 will come into effect immediately. This new order authorizes the National Pharmaceutical Pricing Authority...

Janssen’s ulcerative colitis drug approved by US FDA

17/05/2013

Hannah Blake

Janssen Biotech, one of Johnson & Johnson's pharma companies, has announced the FDA approval of its ulcerative colitis drug, Simponi for use in the US. The FDA has approved Simponi (golimumab)...

Sanofi reports positive phase 3 myelofibrosis study results

17/05/2013

Hannah Blake

Sanofi has announced that its rare disease treatment to treat myelofibrosis showed positive results in a late-stage phase 3 clinical trial. The French drugmaker's pivotal study JAKARTA was evaluating the JAK2...

Open access in medical journals - interv…

Executive perspectives: Bruno Strigini

Doctors hold the key to understanding pa…

Carly Brown

Pharma is recognising the increasing importance of the patient voice in providing feedback on how medicines are utilised in a real-world setting and the impact they are having on outcomes....

Outcomes shape the new payer networks fo…

Marcelo Fantoni

The definition of the payer and the way in which healthcare spending decisions are made is changing, as complex networks of payers and clinicians become the new stakeholders with which...

Publishing white papers on pharmaphorum

Paul Tunnah

As a new feature on pharmaphorum, we unveil pharmaceutical industry white papers as part of our media section. Download this one page document to understand how to publish your deep...